There have been multiple trials that have tried to combine novel anticancer drugs with weekly paclitaxel and these have led to licensing of the anti-VEGF antibody bevacizumab for the treatment of platinum-resistant ovarian cancer [5]. The gene discussed is VEGFA; the disease is ovarian cancer.